Eli Lilly & Co. (LLY)

82.65
1.50 1.90
NYSE : Health Technology
Prev Close 81.14
Open 81.42
Day Low/High 81.42 / 82.72
52 Wk Low/High 73.69 / 89.09
Volume 2.27M
Avg Volume 4.81M
Exchange NYSE
Shares Outstanding 1.09B
Market Cap 87.51B
EPS -0.20
P/E Ratio N/A
Div & Yield 2.25 (2.65%)

Latest News

Is Your Retirement Fund Equipped for You to Live to 100?

Is Your Retirement Fund Equipped for You to Live to 100?

More than half of wealthy investors expect to live to 100. Here's what you need to know to make sure you don't outlive your savings.

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Stocks finished sharply lower Tuesday, as corporate earnings disappoint investors.

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Lilly's chairman and CEO David Ricks said in an earnings call that he was confident in the risk-benefit profile for both proposed doses of the new drug.

Jim's Daily Rundown

Jim discusses Alphabet's earnings, Eli Lilly, 3M and more!

Eli Lilly Reports Strong Beat and Raise

Overall, it was a very strong beat by the company, and we view the ever-important guidance raise as favorable.

Alphabet, Caterpillar, Coca-Cola and Amazon - 5 Things You Must Know

Alphabet, Caterpillar, Coca-Cola and Amazon - 5 Things You Must Know

U.S. stock futures rise while the yield on the 10-year Treasury flirts with 3%; Alphabet beats first-quarter earnings and revenue expectations but there are concerns about rising costs at the search giant; 3M, Coca-Cola and Caterpillar report earnings.

Feels Like the Semis Are Skating on Thin Ice: Market Recon

Feels Like the Semis Are Skating on Thin Ice: Market Recon

Forward looking valuations, except for Nvidia, are very low.

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

Elanco Announces Addition Of Chief Financial Officer

Christopher Jensen to join Indiana-based Animal Health Company's Leadership Team

Weekly Roundup

Markets give up some gains Thursday and Friday, ahead of heavy earnings next week.

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Jim Cramer highlights Spotify, Alkermes, Sorrento Therapeutics, Thermo Fisher Scientific, Kohlberg Kravis Roberts, and more.

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Washington receded and earnings came to the fore, but we're still seeing insane values and some surprises, says Jim Cramer.

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.

Jim's Daily Rundown

Today, Jim discusses Raytheon, tensions in Syria, bank earnings, Kohl's, Nordstrom and more!

Weekly Roundup

The markets bounced back on easing trade tensions and the banks kicked off first-quarter earnings season.

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.

Adding to Kohl's on Weakness

Kohl's is a company with 100% of revenue coming from the United States.

Buying More Lilly

We are picking up LLY shares into weakness, below our basis in the process.

Alkermes Surprised, Angered by FDA Rejection of Antidepressant

Alkermes Surprised, Angered by FDA Rejection of Antidepressant

Alkermes says the rejection of antidepressant drug ALKS 5461 is a head-scratcher, and it's calling for a prompt meeting with the regulator to get to the bottom of the decision.

Women's History Month: Nancy Lieberman -- Still Law Firm's Youngest Partner Ever

Women's History Month: Nancy Lieberman -- Still Law Firm's Youngest Partner Ever

For Women's History Month, Alpha Rising sat down with Nancy Lieberman, Of Counsel at Skadden, Arps. She was and still is the youngest person to ever make partner at her firm. She has worked on some of the biggest M&A deals in history -- and we should mention -- she's in a wheelchair and barely as use of her hands. Feel like a slacker yet? Good. Watch.

Weekly Roundup

Fears of a trade war and a Fed rate hike marked a volatile week.

Eli Lilly: Is the Coast Now Clear for the Bulls?

Eli Lilly: Is the Coast Now Clear for the Bulls?

Traders should stay alert and nimble with LLY stock.

Qualcomm Ex-Chairman's Leveraged Buyout Bid a Real Long Shot

Qualcomm Ex-Chairman's Leveraged Buyout Bid a Real Long Shot

Former Executive Chairman Paul Jacobs is considering a leveraged buyout, which would be incredibly expensive and face tough regulatory scrutiny.

Weekly Roundup

White House gets new economic adviser.

Merck, Phillips 66, Five Below, Cintas: 'Mad Money' Lightning Round

Merck, Phillips 66, Five Below, Cintas: 'Mad Money' Lightning Round

Jim Cramer focuses on Merck, Eli Lilly, Abbott Labs, Phillips 66, Five Below, and Cintas in the Lightning Round.

TheStreet Quant Rating: C+ (Hold)